Tag:

Merck Serono

Latest Headlines

Latest Headlines

Merck Serono, Illumina partner in the latest universal next-gen cancer diagnostic deal

Cancer diagnostics has long been defined by the aim of providing "personalized" and "precision" medicine to patients. But now the buzzword of the moment seems to be trending more toward "universal"--as the industry strives for an all-encompassing test that will mete out the best possible individual treatment protocols based on genomic data.

Billionaire's fund pitches immunotherapy merger for Stallergenes

An investment fund backed by the megarich family that founded Serono has proposed merging Stallergenes and Greer. The fund is well placed to make such a deal happen: It has a 77.3% stake in Stallergenes and owns Greer outright.

Ex-Merck Serono team bags €8.7M for PhI Parkinson's program

Prexton Therapeutics, the first company to emerge from the €30 million ($34 million) biotech-creation program Merck Serono set up amid the shuttering of its Geneva R&D center, has closed a Series A round.

Wellcome Trust, Merck Serono collaborate on cancer drug discovery

Merck Serono is teaming up with London's Institute of Cancer Research and the charitable Wellcome Trust to identify and develop new inhibitors to treat cancer.

Merck Serono steps into IO spotlight with PhII cancer study

Looking to share some of the spotlight focused on the immuno-oncology arena, Merck Serono says it has launched a mid-stage study of MSB0010718C, an anti-PD-L1 antibody.

Merck KGaA targets China with a planned €40M allergy plant

Merck KGaA last year closed manufacturing facilities as part of a major restructuring to cut costs. This year it is planning to build them to serve areas that it has decided have the greatest potential as well as expected growth in emerging markets.

Merck KGaA says big M&A could jump-start stilted pipeline

Merck KGaA is still crawling through a broad restructuring effort, but the German drugmaker said it's keeping an eye out for major deals that could help it piece together a promising pipeline after years of setbacks.

Merck KGaA hikes forecast, eyes deals as cost cuts keep delivering

Once again, Merck KGaA reported a quicker-than-expected payoff from its big cost-cutting program. The German drugmaker hiked its profit forecast for the year, saying the changes it has made are delivering cost savings sooner than it had planned.

Merck Serono's new HQ taps open-office style to encourage innovation

The redesigned buildings on Merck KGaA's campus feature the sort of flexible work stations and open-office arrangements recently adopted by GlaxoSmithKline in Philadelphia and Biogen Idec in Cambridge, MA.

Belén Garijo named Merck Serono CEO

Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...